| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Absence of evidence is not evidence of absence: the case of non-inferiority
|
Klingbiel, D.
|
|
|
28 |
12 |
p. 3100-3101
|
artikel
|
| 2 |
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’
|
Schöffski, P.
|
|
|
28 |
12 |
p. 3000-3008
|
artikel
|
| 3 |
Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a Surveillance, Epidemiology, and End Results Cohort Study, 2000–2013
|
Oseledchyk, A.
|
|
|
28 |
12 |
p. 2985-2993
|
artikel
|
| 4 |
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
|
Necchi, A.
|
|
|
28 |
12 |
p. 3044-3050
|
artikel
|
| 5 |
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients
|
Heppt, M.V.
|
|
|
28 |
12 |
p. 3104-3106
|
artikel
|
| 6 |
Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
|
Varghese, A.M.
|
|
|
28 |
12 |
p. 3015-3021
|
artikel
|
| 7 |
Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework
|
de Hosson, L.D.
|
|
|
28 |
12 |
p. 3022-3027
|
artikel
|
| 8 |
ClonEvol: clonal ordering and visualization in cancer sequencing
|
Dang, H.X.
|
|
|
28 |
12 |
p. 3076-3082
|
artikel
|
| 9 |
Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy
|
Tallet, A.V.
|
|
|
28 |
12 |
p. 2962-2976
|
artikel
|
| 10 |
Correction to: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|
Dreyling, M.
|
|
|
28 |
12 |
p. 3109
|
artikel
|
| 11 |
Correction to: Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial
|
Lonardi, S.
|
|
|
28 |
12 |
p. 3110
|
artikel
|
| 12 |
Correction to: Power and limits of modern cancer diagnostics: cancer of unknown primary
|
Hemminki, K.
|
|
|
28 |
12 |
p. 3112
|
artikel
|
| 13 |
Correction to: 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|
Cardoso, F.
|
|
|
28 |
12 |
p. 3111
|
artikel
|
| 14 |
DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update
|
Henricks, L.M.
|
|
|
28 |
12 |
p. 2915-2922
|
artikel
|
| 15 |
DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?
|
Páez, D.
|
|
|
28 |
12 |
p. 2913-2914
|
artikel
|
| 16 |
Editorial Board
|
|
|
|
28 |
12 |
p. ii-iii
|
artikel
|
| 17 |
Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead
|
Ulahannan, D.
|
|
|
28 |
12 |
p. 2923-2931
|
artikel
|
| 18 |
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)
|
Martin-Broto, J.
|
|
|
28 |
12 |
p. 2994-2999
|
artikel
|
| 19 |
Gougerot-Sjogren-like syndrome under PD-1 inhibitor treatment
|
Teyssonneau, D.
|
|
|
28 |
12 |
p. 3108
|
artikel
|
| 20 |
HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma
|
Koksal, A.S.
|
|
|
28 |
12 |
p. 3103-3104
|
artikel
|
| 21 |
Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
|
Sahin, I.H.
|
|
|
28 |
12 |
p. 2950-2961
|
artikel
|
| 22 |
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review
|
García-Foncillas, J.
|
|
|
28 |
12 |
p. 2943-2949
|
artikel
|
| 23 |
Incremental improvement in osteosarcoma chemotherapy?
|
Schuetze, S.M.
|
|
|
28 |
12 |
p. 2911-2913
|
artikel
|
| 24 |
LAG-3: another brake to release in breast cancer?
|
Kok, M.
|
|
|
28 |
12 |
p. 2907-2908
|
artikel
|
| 25 |
LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors
|
Burugu, S.
|
|
|
28 |
12 |
p. 2977-2984
|
artikel
|
| 26 |
Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab
|
Arnold, D.
|
|
|
28 |
12 |
p. 2932-2942
|
artikel
|
| 27 |
Molecular Tumor Boards: current practice and future needs
|
van der Velden, D.L.
|
|
|
28 |
12 |
p. 3070-3075
|
artikel
|
| 28 |
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study
|
Cremolini, C.
|
|
|
28 |
12 |
p. 3009-3014
|
artikel
|
| 29 |
Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)
|
Argiris, A.
|
|
|
28 |
12 |
p. 3037-3043
|
artikel
|
| 30 |
Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial
|
Glass, B.
|
|
|
28 |
12 |
p. 3058-3064
|
artikel
|
| 31 |
Response to ‘Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest’
|
Bi, N.
|
|
|
28 |
12 |
p. 3101-3103
|
artikel
|
| 32 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2− breast cancer
|
Messina, C.
|
|
|
28 |
12 |
p. 3099-3100
|
artikel
|
| 33 |
Role of adjuvant chemotherapy in early-stage endometrioid and clear-cell ovarian cancer
|
Lorusso, D.
|
|
|
28 |
12 |
p. 2909-2911
|
artikel
|
| 34 |
SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
|
Soria, J.-C.
|
|
|
28 |
12 |
p. 3028-3036
|
artikel
|
| 35 |
Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer
|
Jones, M.R.
|
|
|
28 |
12 |
p. 3092-3097
|
artikel
|
| 36 |
Table of Contents
|
|
|
|
28 |
12 |
p. iv-vi
|
artikel
|
| 37 |
The antibody–drug conjugate target landscape across a broad range of tumour types
|
Moek, K.L.
|
|
|
28 |
12 |
p. 3083-3091
|
artikel
|
| 38 |
The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin’s lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study
|
Zaucha, J.M.
|
|
|
28 |
12 |
p. 3051-3057
|
artikel
|
| 39 |
Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue
|
Butterbaugh, S.T.
|
|
|
28 |
12 |
p. 3098-3099
|
artikel
|
| 40 |
Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab
|
Otsubo, K.
|
|
|
28 |
12 |
p. 3106-3107
|
artikel
|
| 41 |
Understanding personal risk of oropharyngeal cancer: risk-groups for oncogenic oral HPV infection and oropharyngeal cancer
|
D’Souza, G.
|
|
|
28 |
12 |
p. 3065-3069
|
artikel
|
Tijdschrift beschrijving